1. Clinical Considerations in the Use of Checkpoint Inhibitors for Genitourinary Cancers

2. Activity Goals

3. Association of Immune Cell Panel Macrophages With Tumor Recurrence

4. Entinostat and High-Dose IL-2 in RCC

6. CheckMate 025: Nivolumab vs Everolimus in Advanced RCC

7. CheckMate 025: ORR by Key Subgroups

8. IMVigor 210: Atezolizumab in mUC

9. IMVigor 210: Results

10. Atezolizumab: Phase 1 vs Phase 2 Data

11. Phase 2: Gemcitabine + Cisplatin + Ipilimumab in mUC

12. Gemcitabine + Cisplatin + Ipilimumab in mUC: Results

13. Abbreviations